A Phase 3, Prospective, Adaptive, Randomized, Double-blind, Triple-masked, Parallel, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy
Latest Information Update: 12 Dec 2024
Price :
$35 *
At a glance
- Drugs N 0750 (Primary) ; Duloxetine; Pregabalin
- Indications Neuropathic pain; Pain
- Focus Therapeutic Use
- Sponsors Eurofarma
- 12 Dec 2024 New trial record